Moneycontrol PRO
Check Credit Score
Check Credit Score
HomeNewsBusinessStocks

Caplin Point Laboratories gains 4% on EIR from USFDA

This was the third successful US FDA audit at the plant since 2016.

July 25, 2019 / 11:53 AM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Share price of Caplin Point Laboratories added nearly 4 percent intraday on July 25 after company received the establishment inspection report (EIR) from USFDA.

Caplin Steriles, a wholly owned subsidiary of Caplin Point Laboratories, has received the establishment inspection report (EIR) from USFDA for the recently concluded inspection in June 2019, company said in BSE release.

This was the third successful US FDA audit at the plant since 2016.

C.C.Paarthipan, Chairman of Caplin Point Laboratories said, "We're glad to receive the EIR within a short period of completing the inspection. Our commitment to maintaining the highest quality standards remain strong. We're also starting to see traction in terms of product approvals and commercial batches being rolled out of this facility."

At 11:48 hrs Caplin Point Laboratories was quoting at Rs 394.80, up Rs 8.75, or 2.27 percent on the BSE.

Moneycontrol News
first published: Jul 25, 2019 11:53 am

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347